World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0003447944
Reproduction Date:

Title: Hmb-45  
Author: World Heritage Encyclopedia
Language: English
Subject: Histopathology, Melanoma, WikiProject Pharmacology/Drugbox and WP:PHARM crosscheck
Publisher: World Heritage Encyclopedia


HMB-45 is a monoclonal antibody that reacts against an antigen present in melanocytic tumors such as melanomas, and stands for human melanoma black 45. It is used in anatomic pathology as a marker for such tumors. The specific antigen recognized by HMB-45 is now known as Pmel 17.

HMB-45 was discovered by Drs. Allen M. Gown and Arthur M. Vogel in 1986.[1] The antibody was generated to an extract of melanoma. It reacts positively against melanocytic tumors but not other tumors, thus demonstrating specificity and sensitivity.

In a study to determine diagnostic usefulness of specific antibodies used to identify melanoma, HMB-45 had a 92% sensitivity when used to identify melanoma. The antibody also reacts positively against junctional nevus cells and fetal melanocytes.[2]

Despite this relatively high sensitivity—HMB-45 does have its drawbacks. HMB-45 can be detected in only 50-70% of melanomas. HMB-45 does not react well against intradermal nevi, normal adult melanocytes, spindle cell melanomas and desmoplastic melanomas. HMB-45 is nonreactive with almost all non-melanoma human malignancies, with the exception of rare tumors showing evidence of melanogenesis (e.g., pigmented schwannoma, clear cell sarcoma) or tumors associated with tuberous sclerosis complex (angiomyolipoma and lymphangiomyoma).[3]

Storage HMB-45 should be stored at 4 degree Celsius. At 4 degrees Celsius the antibody will be stable for up to 2 months without any loss of quality. For best results it should be used before the expiration date.

Other Antibodies When conducting an immunocytochemical studies to identify melanoma for scientific or clinical studies, scientist and medical professionals can also use S-100, Melan-A, Tyrosinase, and Mitf to identify tumors.

See also


  1. ^ Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA (1986). "Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes". Am. J. Pathol. 123 (2): 195–203.  
  2. ^ [2]
  3. ^ Mahmood, M. N.; Lee, M. W.; Linden, M. D.; Nathanson, S. D.; Hornyak, T. J.; Zarbo, R. J. (2002). "Diagnostic Value of HMB-45 and Anti-Melan a Staining of Sentinel Lymph Nodes with Isolated Positive Cells". Modern Pathology 15 (12): 1288–1293.  


External links

  • Melanoma Marker (HMB45) Antibody -
  • Melanoma antibody (ab787) datasheet -
  • Novus Biologicals HMB-45

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.